Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Target Price at $14.33

Seres Therapeutics, Inc. (NASDAQ:MCRB) has been assigned a consensus recommendation of “Reduce” from the five ratings firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $14.3333.

MCRB has been the topic of several recent research reports. Canaccord Genuity Group upped their target price on shares of Seres Therapeutics from $14.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Seres Therapeutics in a research note on Saturday, September 27th.

Seres Therapeutics Price Performance

NASDAQ:MCRB opened at $20.59 on Friday. The company has a market cap of $180.16 million, a price-to-earnings ratio of -4.48 and a beta of 0.19. Seres Therapeutics has a 1 year low of $6.53 and a 1 year high of $24.67. The stock’s 50 day simple moving average is $17.40 and its two-hundred day simple moving average is $12.61.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.72) by $0.45. As a group, analysts anticipate that Seres Therapeutics will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Seres Therapeutics

A number of large investors have recently made changes to their positions in the company. Vontobel Holding Ltd. lifted its stake in Seres Therapeutics by 15.7% in the first quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company’s stock worth $760,000 after purchasing an additional 147,671 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 89,995 shares during the last quarter. Marshall Wace LLP purchased a new position in Seres Therapeutics in the 2nd quarter worth about $1,016,000. Goldman Sachs Group Inc. lifted its holdings in Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 21,679 shares in the last quarter. Finally, SBI Securities Co. Ltd. grew its stake in Seres Therapeutics by 221.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 48,013 shares in the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.